# Exagen share price today (Exagen Inc., XGN)

> Exagen Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. XGN · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/xgn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $8.34 (−28.5% in a year)
- Revenue (Jun 2026): $19.9 M (+15.9% on a year ago)
- Profit (Jun 2026): −$3.2 M
- Operating margin: −8.6% (+6.7 points on a year ago)
- ROE: −114%, FY25
- ROIC: −19.2%, against a 15.8% cost of capital: −35.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Exagen share price today? Exagen Inc.'s share price was $8.34 at the close on 3 November 2026. That is 64.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $10, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 26 weeks in a row. Over the last 1 year the share price moved +19% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Exagen pay? Exagen Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Exagen on? Exagen is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Exagen profitable? Exagen Inc. posted a net loss of $3.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $20.0 M. That loss is 16.0% of the quarter's revenue. The same quarter a year earlier lost $4.4 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Exagen make, and is it growing? Exagen Inc. reported $19.9 M of revenue in the Jun 2026 quarter, +15.9% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 8.4% a year on average. The last full year, FY25, came in at $66.6 M. The last four reported quarters add to $71.1 M. FY25 revenue was $66.6 M, +19.7% on the year before. Recent pace: the last four quarters grew +21.8% on average, against 8.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +20.8%, against +12.0% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Exagen keep? Exagen Inc.'s operating margin was −8.6% in the Jun 2026 quarter, 6.7 percentage points higher than the same quarter a year ago. Across 5 years it has been between −88.1% and −21.1%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +6.7 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Exagen's profit turning into cash? Exagen Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $13.6 M of cash, against −$20.0 M of profit. After $641 K of spending on assets, free cash was −$14.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Exagen's cash go? Exagen Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.0 M on assets over the last 3 years. Averaged over those years that is 1.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.0 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Exagen's P/E ratio, and how does it compare with its own history? Exagen Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Exagen Inc. at 3.0× its FY25 revenue of $66.6 M. The P/E comes back here once profit turns positive. ## Is the Exagen business getting better or worse? Exagen Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Exagen earn on its capital? Exagen Inc. earned a ROE of −114% in FY25. That is up from a low of −158% in FY24. Its return on capital used (ROIC) is 35.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −30.0% net margin and 1.15× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −30.0% net margin × 1.15× asset turnover × 3.33× leverage (assets divided by equity) ≈ −114.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −19.2% − 15.8% = −35.0 percentage points. The 15.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Exagen have too much debt? Exagen Inc. has total debt of $27.7 M against shareholder equity of $12.2 M as of Jun 2026, so its debt is 2.26× its equity. Year by year, that ratio went from 0.33 in FY21 to 1.59 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Exagen shareholding pattern? 5.0% of Exagen Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Exagen from balance-sheet trouble? For Exagen Inc., the Z-score is −5.26. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −5.26 is inside the danger zone, so the balance sheet is a real risk. ## How does Exagen rank in its industry? There is no score against its industry: Exagen Inc. is not among the largest members shown in this industry comparison for Diagnostics & Research. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Exagen compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Exagen in size? Exagen is the 34th largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Personalis, Inc., OPKO Health, Inc., Castle Biosciences, Inc., Myriad Genetics, Inc., Fulgent Genetics, Inc. and Biodesix, Inc. It is the smallest. ### Diagnostics & Research companies close in size

1. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) $1.7 billion
2. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) $1.3 billion
3. [Castle Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/cstl) $1.1 billion
4. [Myriad Genetics, Inc.](https://www.sectoralpha.in/us/stocks/mygn) $578 million
5. [Fulgent Genetics, Inc.](https://www.sectoralpha.in/us/stocks/flgt) $533 million
6. [Biodesix, Inc.](https://www.sectoralpha.in/us/stocks/bdsx) $222 million
7. Exagen Inc. $202 million

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Protalix BioTherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/plx) $209 million · Biotechnology
2. [Chicago Atlantic BDC, Inc.](https://www.sectoralpha.in/us/stocks/lien) $208 million · Asset Management
3. Exagen Inc. $208 million
4. [Silvaco Group, Inc.](https://www.sectoralpha.in/us/stocks/svco) $208 million · Software - Application
5. [Gorilla Technology Group Inc.](https://www.sectoralpha.in/us/stocks/grrr) $207 million · Software - Infrastructure

## What else do people ask about Exagen? ### What were Exagen's latest quarterly results? Exagen Inc. reported revenue of $19.9 M and a net loss of $3.2 M for the Jun 2026 quarter. Earnings per share were −$0.13. The operating margin was −8.6%, 6.7 percentage points higher than a year earlier (as of 3 November 2026). ### What is Exagen's market cap? Exagen Inc.'s market capitalisation is $202 M at a stock price of $8.34. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Exagen performing? Exagen Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 26 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Exagen's stock price go up? This page does not forecast Exagen Inc.'s stock price. What it shows instead: the stock price is $8.34. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Exagen in its business cycle? Exagen Inc.'s FY25 operating margin was −21.1%, against a 5-year range of −88.1% to −21.1%: the middle of its own range, neither a peak nor a low. The latest quarter was −8.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Exagen story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Exagen a stock worth studying right now? What the numbers show: Exagen Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.